Stocks

VANCOUVER, British Columbia, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Tree Island Steel (''Tree Island'' or the ''Company'') (TSX: TSL) announced today its financial results for the nine months ended September 30, 2023. For the three-month period ended September 30, 2023, revenues decreased by $26.8 …

Q3 2023 revenue of $615 million, an increase of $52 million, or 9%, over Q3 2022. Q3 2023 Adjusted EBITDA* of $39 million, representing an Adjusted EBITDA* margin of 6%. Q3 2023 net income of $8 million or $0.35 per share compared with $11 …

Altus Group Limited Steady Year-over-Year Recurring Revenue Growth & Margin Expansion at Analytics; Free Cash Flow Generation Begins To Inflect TORONTO, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Altus Group Limited (ʺAltus” or “the Company”) (TSX: AIF), a leading provider of asset and fund intelligence …

CALGARY, Alberta, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Condor Energies Inc. (“Condor” or the “Company”) (TSX:CDR), a Canadian based energy transition company with activities in Turkiye and Kazakhstan is pleased to announce the release of its unaudited interim condensed consolidated financial statements for the …

TerrAscend Net Revenue of $89.2 million, an increase of 34.7% year-over-year and 23.7% sequentially Gross Profit margin of 53.6%, a 340-basis point sequential improvement from 50.2% in Q2 2023 Adjusted EBITDA from continuing operations1 of $24.2 million, an increase of 89% sequentially, representing a …

AVITA Medical VALENCIA, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (the “Company”), a regenerative medicine company leading the development and commercialization of first-in-class devices and autologous cellular therapies for skin restoration, today reported financial results for the …

Tuspetinib (TUS) Targets Venetoclax (VEN) Resistance Mechanisms TUS/VEN Combination Therapy Active in R/R VEN Failure AML Patients – Guides Toward Accelerated Approval Path, Including FLT3 Mutated and Wildtype TUS/VEN Overall Response Rate of 48% in Heavily Pre-Treated Relapsed/Refractory AML Patients Tuspetinib Favorable Safety Profile …